Study S002051

A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, When Administered as a Single Dose in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT04159766
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 20
Start: 2019-10-16
Primary completion: 2020-12-04
Lead sponsor: Neuraly, Inc.
Conditions: Type2 Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:NLY01; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Number of participants with Treatment Emergent Adverse Events [35 days]
Number of Incidences of Adverse Events [35 days]
Plasma glucose [24 hours]
Change in serum insulin [24 hours]
Change in plasma glucagon [24 hours]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.